Moderna
Web results:
We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer and infectious diseases. As immune engineers we have a deep understanding of the underlying mechanisms that enable the immune system to effectively recognize both external threats like infectious diseases and internal threats like cancer.
Pfizer-BioNTech COVID-19 Vaccine is a monovalent COVID-19 vaccine that is authorized for emergency use to prevent COVID-19 as: The first two doses of the three-dose primary series for children 6...
Analyst Report: BioNTech SE BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for...
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, and Christoph Huber, with a seed investment of €150 million from MIG Capital and AT Impf. The company's activities focus on the development and production of technologies and drugs for individualized cancer immunotherapy.
BioNTech announced in September 2020, that it had signed an agreement to acquire a manufacturing facility in Marburg, Germany, from Novartis to expand their vaccine production capacity. Once fully operational, the facility would produce up to 750 million doses per year, or more than 60 million doses per month. The site will be the third BioNTech facility in Europe that produces the vaccine, while Pfizer operates at least four production sites in the United States and Europe.
3. Biontech-Firmengebäude in Mainz, 2020. (Foto: Marcus Krauss / AdobeStock) Fachkräftemangel, zunehmende Bürokratie, langsame Prozesse: Das Mainzer Pharma-Vorzeigeunternehmen Biontech zieht es ...
Marc O. Schmidt-Kolumne. In den vergangenen Tagen herrschte große mediale Aufregung rund um Biontech (WKN: A2PSR2 / ISIN: US09075V1026). Fälschlicherweise hieß es bereits vonseiten einiger ...